Nanjing Leads Biolabs Co Ltd (09887.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	231.4M	197.2M	—	9.8M	—
Cost of Revenue	—	—	—	3.5M	17.8M
Gross Profit	231.4M	197.2M	—	6.3M	(17.8M)
Operating Expenses
R&D Expense	364.5M	321.6M	27.1M	254.0M	172.7M
SG&A Expense	93.1M	92.0M	12.8M	41.9M	23.1M
General & Admin Expense	92.7M	91.6M	12.7M	41.3M	—
Selling & Marketing Expense	369.4K	446.1K	62.1K	567.8K	—
Other Expenses	8.00	8.00	—	—	—
Total Operating Expenses	457.5M	413.6M	39.8M	295.9M	195.8M
Cost and Expenses	457.5M	413.6M	39.8M	299.4M	213.5M
Operating Income (EBIT)	(226.1M)	(216.4M)	(39.8M)	(289.6M)	(213.5M)
Non-Operating
Interest Income	—	28.8M	8.3M	6.6M	2.4M
Interest Expense	—	7.0M	5.8M	1.4M	303.3K
Net Interest Income	43.0M	21.8M	2.5M	5.2M	2.1M
Other Non-Op Income/Expense	(25.3M)	(1.5M)	(4.1M)	(109.0M)	(73.2M)
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	(251.4M)	(217.9M)	(43.9M)	(398.6M)	(286.8M)
Income Tax Expense	20.2M	17.3M	—	—	—
Bottom Line
Net Income	(271.6M)	(235.2M)	(43.9M)	(398.6M)	(286.8M)
Earnings from Cont. Ops	(271.6M)	(235.2M)	(43.9M)	(398.6M)	(286.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(271.6M)	(235.2M)	(43.9M)	(398.6M)	(286.8M)
Per Share
Basic EPS	(HK$1.38)	(HK$1.35)	(HK$0.29)	(HK$2.76)	(HK$1.51)
Diluted EPS	(HK$1.38)	(HK$1.35)	(HK$0.29)	(HK$2.76)	(HK$1.51)
Revenue Per Share	HK$1.17	HK$1.13	HK$0.00	HK$0.07	HK$0.00
Shares
Basic Shares Outstanding	197.0M	174.1M	150.0M	144.9M	188.6M
Diluted Shares Outstanding	197.0M	174.1M	150.0M	144.9M	188.6M
Profitability Metrics
EBITDA	(208.4M)	(199.0M)	(36.9M)	(267.9M)	(195.8M)
D&A	17.7M	17.4M	2.9M	21.7M	17.8M
EBIT	(226.1M)	(216.4M)	(39.8M)	(289.6M)	(213.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026